<--- Back to Details
First PageDocument Content
Health / Pharmaceuticals policy / Pharmacology / Food law / Structured Product Labeling / New Drug Application / Prescription Drug User Fee Act / Title 21 of the Code of Federal Regulations / Pharmaceutical industry / Medicine / Food and Drug Administration / Pharmaceutical sciences
Health
Pharmaceuticals policy
Pharmacology
Food law
Structured Product Labeling
New Drug Application
Prescription Drug User Fee Act
Title 21 of the Code of Federal Regulations
Pharmaceutical industry
Medicine
Food and Drug Administration
Pharmaceutical sciences

SOPP 8412: Review of Product Labeling Version # 4 Effective Date: April 2, 2012 I. Purpose This SOPP outlines the general operating procedures for Center for Biologics Evaluation and Research (CBER) staff to process draf

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 78,63 KB

Share Document on Facebook

Similar Documents

Capital Reporting Company Public Meeting on PDUFA VIU.S. FOOD & DRUG ADMINISTRATION PRESCRIPTION DRUG USER FEE ACT

Capital Reporting Company Public Meeting on PDUFA VIU.S. FOOD & DRUG ADMINISTRATION PRESCRIPTION DRUG USER FEE ACT

DocID: 1t0K4 - View Document

Prescription Drug User Fee Act (PDUFA) Reauthorization Public Meeting August 15, 2016 1  Basic PDUFA Construct

Prescription Drug User Fee Act (PDUFA) Reauthorization Public Meeting August 15, 2016 1 Basic PDUFA Construct

DocID: 1sUEh - View Document

Prescription Drug User Fee Act (PDUFA) Reauthorization August 15, 2016  Page 1 1  FOOD AND DRUG ADMINISTRATION (FDA)

Prescription Drug User Fee Act (PDUFA) Reauthorization August 15, 2016 Page 1 1 FOOD AND DRUG ADMINISTRATION (FDA)

DocID: 1sUz3 - View Document

United States Government Accountability Office  GAO Testimony Before the Subcommittee on Oversight

United States Government Accountability Office GAO Testimony Before the Subcommittee on Oversight

DocID: 1rfHg - View Document

Best Practices in Developing Proprietary Names for Drugs

Best Practices in Developing Proprietary Names for Drugs

DocID: 1r8R5 - View Document